← All trials
NCT05607550
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2022
- Primary completion
- Aug 15, 2025
- Completion date
- Feb 15, 2028
- First posted
- Nov 7, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 375
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ArriVent BioPharmaLead sponsor
- Allist Pharmaceuticals, Inc.Collaborator
- ArriVent BioPharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.